Orchestra BioMed新闻 - Orchestra BioMed在2024年CRT会议上宣布了两个口头报告[1] - Virtue SAB是一种新型药物释放球囊成形术系统，可以传递sirolimus的专有延长释放配方SirolimusEFR™到血管壁[2] - AVIM疗法是一种通过标准双腔起搏器传递的治疗方法，可以降低血压[3]

业绩总结 - Medtronic在过去一年连续五个季度实现了中单位数的营收增长[4] - 公司预计在第四季度和未来几个季度将实现增长，特别是在美国市场[15] - 公司对未来业绩表现充满信心[38] 用户数据 - Medtronic的产品线包括心脏消融、糖尿病、脑部刺激等领域，且拥有强大的产品管道[4] - Medtronic在心脏消融领域推出了PulseSelect和Affera产品，受到医生们的积极反馈[11] - Medtronic的手术机器人Hugo在全球四大洲都有市场，受到医生和医疗机构的好评[28] 未来展望 - 公司将在5月份的财报电话会议上公布2025财年的业绩指引[32] - 公司预计EV-ICD产品将成为长期增长驱动力，市场规模预计将大幅增长[22] - 公司将在未来推出Evolut FX Plus产品，以进一步提高市场份额[26] 新产品和新技术研发 - 糖尿病业务在欧洲推出了Simplera Sync传感器，预计将在美国市场提交FDA审批[6] 市场扩张和并购 - 公司在努力降低成本和提高产品定价以抵消通货膨胀的影响[34] 负面信息 - 货币汇率对公司业绩造成了一定的负面影响[34] - 全球税收改革可能会继续对公司造成负面影响[34]

Medtronic plc (NYSE:MDT) 2024 Barclays 26th Annual Healthcare Conference Call March 12, 2024 8:00 AM ET Company Participants Karen Parkhill - CFO Conference Call Participants Matt Miksic - Barclays Matt Miksic Good morning. Thanks so much for joining us. My name is Matt Miksic, I’m US Medical Device Analyst here at Barclays, and we are very pleased to have with us today Medtronic, specifically, CFO, Karen Parkhill, so thanks again so much for joining us. Karen Parkhill Thank you, Matt. Great to be here. Mat ...

Medtronic plc (MDT) is likely to grow in the coming quarters, backed by remarkable progress within the Cardiovascular portfolio. The Cranial and Spinal technologies business within the company’s Neuroscience portfolio has been registering strong growth in recent quarters. Favorable solvency is highly encouraging.Meanwhile, macroeconomic challenges may have an adverse impact on the company’s operations. Intense competition from peers is also concerning.In the past year, this Zacks Rank #3 (Hold) stock has in ...

Just_Super/iStock via Getty Images Medtronic PLC (NYSE:MDT) is a global developer and manufacturer of medical devices for chronic diseases. Founded in 1949, Medtronic is now a $111 billion (by market cap) healthcare behemoth that employs 95,000 people. The company reports results across four segments: Cardiovascular, 37% of FY 2023 revenue; Neuroscience, 29%; Medical Surgical, 27%; and Diabetes, 7%. Medtronic’s product portfolio is comprised of a variety of life-saving and life-improving medical devices ...

Medtronic plc (MDT) recently presented a set of new clinical and real-world evidence on the MiniMed 780G system from around the world. The latest data reveals that the system withstands strong global performance, exceeding international targets for diabetes management.The data was presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy.Study DetailsAccording to the business, the findings are built on three years of data published in Diabe ...

Key PointsMedtronic is a leading medical device maker known for inventing the world's first portable and implantable pacemaker.Medtronic is a Dividend Aristocrat that's consistently raised its dividend payments for 46 consecutive years.Medtronic beat its fiscal Q3 2024 EPS by 15 cents, grew revenues by 4.7% YoY and raised its fiscal full-year 2024 guidance along with adding $5 billion to its stock buyback program.5 stocks we like better than MedtronicMedical device maker Medtronic PLC NYSE: MDT is a Dividen ...

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measuresDUBLIN and FLORENCE, Italy, March 9, 2024 /PRNewswire/ -- Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data from early users in the United States. The data was presented at the 17th Internatio ...

Board authorizes $5 billion for share repurchases DUBLIN, March 7, 2024  /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 7, 2024, approved the company's cash dividend for the fourth quarter of fiscal year 2024 of $0.69 per ordinary share. This quarterly declaration is consistent with the dividend announcement made by the company in May 2023.  Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past ...

Clinical study evaluated impact of AVIM therapy as compared to standard pacing using invasive pressure-volume loop analysis in 16 hypertensive pacemaker-indicated patients Results demonstrate statistically significant reductions in systolic blood pressure, intra-cardiac volumes, total peripheral resistance and stroke work, with no significant changes in stroke volume or contractility. AVIM therapy showed consistent favorable hemodynamic effects using both conduction system pacing, as well as traditional rig ...